Novo NordiskNovo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their footprint.
Tag Archive for: MASH
Henk Vrieselaar - stock.adobe.com Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.